This meta-analysis of 10 clinical trials evaluated duloxetine’s impact on body weight in patients with major depressive disorder (MDD). Short-term treatment (8–9 weeks) with duloxetine (40–120 mg/day) resulted in modest weight loss (mean: -0.5 to -0.6 kg), likely due to side effects such as decreased appetite and nausea. Long-term treatment
This 2002 randomized, double-blind study evaluated weight changes over 26–32 weeks in 284 patients with major depressive disorder treated with fluoxetine, sertraline, or paroxetine. Paroxetine-treated patients experienced a significant average weight gain of 3.6%, with 25.5% gaining more than 7% of their baseline weight. In contrast, fluoxetine-treated patients had a
This 2-year, multicenter, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of orlistat (120 mg three times daily) in 743 obese patients (BMI 28–47 kg/m²) across 15 European centers. Following a 4-week lead-in period with a hypocaloric diet, 688 participants were randomized to receive orlistat or placebo alongside dietary
This pooled analysis of two prospective observational registry studies evaluated the long-term effects of testosterone undecanoate therapy in 156 obese hypogonadal men with type 2 diabetes mellitus (T2DM) over a period of up to 6 years. Testosterone treatment led to significant and sustained reductions in weight (mean loss of 17.49
This 2013 observational study evaluated the effects of long-term testosterone therapy in 261 hypogonadal men aged 32–84 years. Participants received parenteral testosterone undecanoate 1000 mg every 12 weeks over a 5-year period. Results demonstrated progressive and sustained reductions in body weight (from 100.1 ± 14.0 kg to 92.5 ± 11.2
This 24-month randomized controlled trial (PMID: 12695131) assessed the efficacy and tolerability of finasteride 1 mg daily in 424 men aged 41–60 with mild-to-moderate vertex male pattern hair loss. Finasteride significantly improved hair growth compared to placebo starting at month 6 (p < 0.001) and continued through month 24, as
This randomized controlled trial evaluated the long-term efficacy of finasteride 1 mg/day in preventing further visible hair loss in men with androgenetic alopecia (AGA). Analyzing data from 1,553 participants across two Phase III studies, the results showed that daily finasteride use led to a 93% reduction in the 5-year likelihood
Clomiphene citrate was evaluated in a study focused on its long-term safety and efficacy for treating hypogonadism, specifically in men with testosterone levels below 300 ng/dl. The study found significant improvements in testosterone levels and symptom relief, including reduced fatigue and increased libido, over extended periods (more than three years).
Long-term testosterone therapy (TTh) with injectable testosterone undecanoate significantly improved glycemic control and led to diabetes remission in men with hypogonadism and type 2 diabetes mellitus (T2DM) over an 11-year observational study. Among the 178 testosterone-treated patients, 34.3% achieved diabetes remission, 46.6% attained normal glucose regulation, and over 80% reached
